Evaluation of autonomy and care experience in multiple sclerosis when initiating subcutaneous ocrelizumab

Patient Evaluation of Autonomy and Care Experience in multiple sclerosis when initiating ocrelizumab SC in real-world settings: the PEACE study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN31489759

Enrollment

750

Registered

2026-01-27

Start date

2026-02-09

Completion date

Unknown

Last updated

2026-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsing-remitting multiple sclerosis (RRMS) Nervous System Diseases

Interventions

Adult patients with RRMS initiating ocrelizumab SC (920 mg) as part of their routine clinical care will be observed for 24 months. Data will be collected via electronic Case Report Forms (eCRF) and Pa

Eligibility

Sex/Gender

All

Age

18 Years to 120 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosis of RRMS according to the 2017 or 2024 revised McDonald criteria 2. Age 18 years or older 3. Initiation of ocrelizumab SC planned by the healthcare professional (either as a switch from specific prior therapies or in treatment-naïve patients) 4. Physically and cognitively able to complete the study questionnaires and tests 5. Possession of a smartphone, tablet, or computer with an internet connection 6. Non-opposition to participation and data processing

Exclusion criteria

Exclusion criteria: 1. Administration of ocrelizumab SC not in accordance with the standard of care or the current Summary of Product Characteristics (SmPC). 2. Patient under guardianship or judicial protection.

Countries

France

Contacts

Public ContactAlexandre;Guillaume Civet;Bourel

;

alexandre.civet@roche.com;guillaume.bourel@roche.com+33 (0)6 28 77 22 28;+33 (0)6 22 08 16 49

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 19, 2026